Ugurel S, Rappl G, Tilgen W, Reinhold U
Department of Dermatology, Saarland University Hospital, Homburg/Saar, Germany.
J Clin Oncol. 2001 Jan 15;19(2):577-83. doi: 10.1200/JCO.2001.19.2.577.
To determine the predictive value of the angiogenic serum factors angiogenin, vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and interleukin-8 (IL-8) for the prognosis of patients with malignant melanoma.
Angiogenin, VEGF, bFGF, and IL-8 were measured in sera of 125 melanoma patients with different stages of disease and with or without current therapy including interferon alfa and different cytostatics in comparison with 30 healthy controls using enzyme-linked immunosorbent assay.
Serum levels of angiogenin, VEGF, bFGF, and IL-8 were significantly increased in melanoma patients compared with healthy controls. Elevated serum concentrations of VEGF, bFGF, and IL-8 were associated with advanced disease stages and tumor burden. Cytostatic therapy of patients was accompanied by increased serum levels of angiogenin, bFGF, and IL-8. As shown by univariate analysis, elevated serum levels of VEGF (P = .0001 and .0036), bFGF (P < .00005 and < .00005), and IL-8 (P < .00005 and < .00005) were strongly correlated with a poor overall and progression-free survival, respectively. Multivariate analysis revealed stage of disease (P = .0238), tumor burden (P = .0347), VEGF (P = .0036), bFGF (P = .0252), and IL-8 (P = .0447) as independent predictive factors of overall survival. Tumor burden (P = .0081), VEGF (P = .0245), and IL-8 (P = .0089) were found as independent predictive factors of progression-free survival.
Our data suggest that the angiogenic serum factors VEGF, bFGF, and IL-8 are useful predictive markers for overall and progression-free survival in melanoma patients.
确定血管生成血清因子血管生成素、血管内皮生长因子（VEGF）、碱性成纤维细胞生长因子（bFGF）和白细胞介素-8（IL-8）对恶性黑色素瘤患者预后的预测价值。
采用酶联免疫吸附测定法，对125例处于不同疾病阶段、接受或未接受包括干扰素α和不同细胞抑制剂在内的当前治疗的黑色素瘤患者的血清进行血管生成素、VEGF、bFGF和IL-8检测，并与30名健康对照者进行比较。
与健康对照者相比，黑色素瘤患者血清中的血管生成素、VEGF、bFGF和IL-8水平显著升高。血清VEGF、bFGF和IL-8浓度升高与疾病晚期和肿瘤负荷相关。患者接受细胞抑制剂治疗后，血清血管生成素、bFGF和IL-8水平升高。单因素分析显示，血清VEGF水平升高（P = 0.0001和0.0036）、bFGF水平升高（P < 0.00005和 < 0.00005）以及IL-8水平升高（P < 0.00005和 < 0.00005）分别与总体生存率和无进展生存率低密切相关。多因素分析显示，疾病分期（P = 0.0238）、肿瘤负荷（P = 0.0347）、VEGF（P = 0.0036）、bFGF（P = 0.0252）和IL-8（P = 0.0447）是总体生存的独立预测因素。肿瘤负荷（P = 0.0081）、VEGF（P = 0.0245）和IL-8（P = 0.0089）被发现是无进展生存的独立预测因素。
我们的数据表明，血管生成血清因子VEGF、bFGF和IL-8是黑色素瘤患者总体生存和无进展生存的有用预测标志物。
